Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SSGJ 613

Next Previous
X
Search
Drug Profile

SSGJ 613

Alternative Names: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection - Sunshine Guojian Pharmaceutical; SSGJ-613; SSGJ-613 100mg

Latest Information Update: 21 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunshine Guojian Pharmaceutical
  • Class Antigouts; Antipyretics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gouty arthritis
  • Phase I/II Gout
  • Phase I Fever; Juvenile rheumatoid arthritis

Most Recent Events

  • 12 Jun 2024 Efficacy and adverse events data from a phase Ib/II trial in Gout presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 30 Mar 2024 Phase-II clinical trials in Gouty arthritis (Prevention) in China (SC) (NCT06270225)
  • 21 Feb 2024 Sunshine Guojian Pharmaceutical plans a phase II trial for Gouty-arthritis (Prevention) (SC, Injection) (NCT06270225)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top